Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology

Response rate approximately doubled compared to previous studies with durvalumab alone in refractory head and neck cancer Danvatirsen, Ionis' most advanced Generation 2.5 antisense drug, demonstrated potential to treat intractable cancers CARLSBAD, Calif., Oct. 22, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) reported new data today on danvatirsen (formerly IONIS-STAT3-2.5Rx, also known as AZD9150) presented at the 2018 European Society for Medical Oncology (ESMO) Annual Congress. The study showed clinical and safety results from a phase 1b/2 trial evaluating danvatirsen, a Generation 2.5 antisense therapy targeting signal transducer and activator of transcription 3 (STAT3), in combination with durvalumab, AstraZeneca's anti-PD-L1 (programmed death ligand-1) antibody, in recurrent metastatic head and neck cancer. The combination treatment resulted in 7% of patients achieving a complete tumor response and 23% achieving either a partial or complete tumor response. This response rate is estimated to be double that with durvalumab alone, based on previous studies in this difficult to treat patient population.

The release as fetched from its publisher. ionis.com ↗